Werewolf Therapeutics, Inc.·Healthcare

Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler & Co. (“Piper Sandler”) to serve as exclusive financial advisor to assist in the strategic evaluation process.

Shares of Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) have earned a consensus recommendation of "Hold" from the seven research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the

Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) Director Luke Evnin sold 24,678 shares of the firm's stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $0.61, for a total value of $15,053.58. Following the completion of the sale, the director directly owned 2,368,849 shares
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.